Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Myeloid 1Lymphoid 1Head & Neck 1Genitourinary 1CNS 1Breast 1

Conditions

Brain Neoplasms 290Glioblastoma 260Glioma 202Neuroblastoma 88Neoplasms 62Astrocytoma 56Central Nervous System Neoplasms 54Medulloblastoma 48Breast Neoplasms 44Melanoma 40Sarcoma 39Meningioma 39Neurofibromatosis 1 38Carcinoma, Non-Small-Cell Lung 38Lung Neoplasms 37Ependymoma 36Osteosarcoma 31Rhabdomyosarcoma 30Neoplasm Metastasis 28Sarcoma, Ewing 27Rhabdoid Tumor 27Diffuse Intrinsic Pontine Glioma 27Recurrence 26Oligodendroglioma 23Gliosarcoma 22Wilms Tumor 21Pancreatic Neoplasms 21Pheochromocytoma 20Hepatoblastoma 20Neurofibroma, Plexiform 19

Interventions

temsirolimus 1Valproic Acid 1Sirolimus 1Immunoglobulin G 1Disulfides 1Cetuximab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphangioleiomyomatosis × CNS × 90 days × Clear all
NCT01552434 2026-05-15

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

Phase 1 Terminated
154 enrolled
BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡